Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (32)	1/25/1999 6:25:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

GLGC just recently made the announcement of the agreement with AFFX to use their (AFFX) chip and so I wonder what GLGC plans is the market/use for the flow through chip. What I got from Dr. Brennen's talk was that they only put something on the order of 100 "important" genes on the flow through chip--whereas while the affx chip has it's place, the fact that it has 50,000 data points on it makes it a lot more expensive-- and maybe it is slow too... Regarding chips, Brennen also said that the flow through chip is something like 40 times faster...very important for high throughput screening...and that they "will have profiling chips shortly". --Mike